Devonian Health Group, Inc.

As of April 30, 2026, Devonian Health Group, Inc. carries a market capitalization of 33.09M, placing it among publicly traded companies globally. Its enterprise value stands at 32.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Devonian Health Group, Inc. has 2.78M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 10.70, and the price-to-book ratio stands at 4.74.

These figures are as of April 30, 2026. The EV/Sales ratio of 10.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 32.51M versus a market cap of 33.09M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, Devonian Health Group, Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.01, indicating elevated leverage, while an interest coverage ratio of -690.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended April 30, 2026, Devonian Health Group, Inc. posted a negative return on equity (ROE) of -77.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.71, reflecting losses generated across the asset base. The company generates approximately 272,296.55 in revenue per employee across its workforce of 11.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 35.76 indicates how many times Devonian Health Group, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended April 30, 2026, Devonian Health Group, Inc. recorded an income tax benefit of -12,684.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -6.13M and -6.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 21, 2026, Devonian Health Group, Inc.'s stock has declined approximately 30.39% over the past 52 weeks. The 50-day moving average sits at 8.72, while the 200-day moving average is 10.20.

Over the twelve months ended April 30, 2026, Devonian Health Group, Inc. generated 3.00M in revenue and converted that into -6.11M in net income, yielding earnings per share of -2.27. EBITDA reached -5.98M, while operating income came in at -6.19M.

As of April 30, 2026, Devonian Health Group, Inc. holds 719,932.00 in cash and equivalents against 140,543.00 in total debt, resulting in a net debt position of -719,932.00. Total book value stands at 6.98M, with working capital of -5,177.00 providing operational flexibility.

Devonian Health Group, Inc. produced -11.77M in operating cash flow over the twelve months ended April 30, 2026. After subtracting -6,500.00 in capital expenditures, free cash flow totaled -11.77M - equivalent to -4.37 per share.

Over the twelve months ended April 30, 2026, Devonian Health Group, Inc. posted a gross margin of 67.89, reflecting its pricing power and cost economics. The operating margin of -206.69 and net profit margin of -204.08 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -36.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.26, meaning Devonian Health Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Devonian Health Group, Inc.'s most recent stock split took place on January 23, 2026 with a 60:1 split ratio.

As of April 30, 2026, Devonian Health Group, Inc. has an Altman Z-Score of -7.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.